Rock Springs Capital Management’s TherapeuticsMD TXMD Stock Holding History

Rock Springs Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-23,456	Closed	-$5.71M	–	152
2018 Q1	$5.71M	Sell	23,456 -44	-0.2%	-$12.3K	0.24%	112
2017 Q4	$7.1M	Sell	23,500 -8,500	-27%	-$2.37M	0.32%	90
2017 Q3	$8.46M	Hold	32,000	–	–	0.39%	82
2017 Q2	$8.43M	Hold	32,000	–	–	0.43%	69
2017 Q1	$11.5M	Sell	32,000 -2,400	-7%	-$743K	0.66%	49
2016 Q4	$9.92M	Sell	34,400 -1,600	-4%	-$496K	0.66%	49
2016 Q3	$12.3M	Buy	36,000 +4,500	+14%	+$1.64M	0.77%	44
2016 Q2	$13.4M	Hold	31,500	–	–	0.99%	35
2016 Q1	$10.1M	Buy	31,500 +7,800	+33%	+$2.66M	0.84%	38
2015 Q4	$12.3M	Buy	23,700 +8,200	+53%	+$3.03M	0.93%	35
2015 Q3	$4.54M	Buy	+15,500	New	+$5.51M	0.37%	88

Other funds holding TXMD

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Rock Springs Capital Management's TXMD Position: Q2 2018 in Review

Rock Springs Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2018, closing a stake of 23,456 shares — an estimated $5.71M sold.

Rock Springs Capital Management first reported a position in TXMD in Q3 2015 and held it in 11 quarters. The position peaked at $13.4M in Q2 2016. 143 funds tracked by Wall St. Rank hold TXMD as of Q2 2018.

Rock Springs Capital Management reported no remaining TherapeuticsMD position as of Q2 2018 after selling out during the quarter.
Rock Springs Capital Management sold 23,456 TherapeuticsMD shares in Q2 2018, an estimated $5.71M.
Rock Springs Capital Management first reported a position in TherapeuticsMD in Q3 2015 and held it in 11 quarters.
Rock Springs Capital Management's TherapeuticsMD position peaked at $13.4M in Q2 2016.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2018.

Based on Rock Springs Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.